DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nafenopin
Nafenopin
A Toxicogenomic Study of the Hepatocarcinogen Furan
Addition of Peroxisome Proliferator-Activated Receptor to Guinea Pig Hepatocytes Confers Increased Responsiveness to Peroxisome
Clofibrate Causes an Upregulation of PPAR- Target Genes but Does Not
BREAST CANCER METASTATIC DORMANCY and EMERGENCE, a ROLE for ADJUVANT STATIN THERAPY by Colin Henry Beckwitt Bachelor of Science
Lipid Screening in Childhood and Adolescence For
Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Ppars, Rxrs, and Drug-Metabolizing Enzymes
(12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Lipid Screening in Childhood and Adolescence For
Lipid Screening in Childhood and Adolescence For
(12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
Liver Fatty Acid-Binding Protein
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: a Systematic Evidence Review for the U.S
Pharmaabkommen A1 E
Customs Tariff - Schedule Xxi - 1
Top View
WO 2010/024870 Al
(12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al
Proposed OPPTS Science Policy: PPAR-Alpha Mediated
Mesh Terms for 2002
Effects of the Hepatocarcinogen Nafenopin, a Peroxisome
(12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari Et Al
Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: a Systematic Evidence Review for the U.S
Structural Alert/Reactive Metabolite Concept As Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxici
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2007/016766 Al
MANAGING BLOOD CHOLESTEROL in ADULTS: SYSTEMATIC EVIDENCE REVIEW from the CHOLESTEROL EXPERT PANEL, 2013 Iii